PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer

References

• Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851–862. doi:10.1001/jama.2021.13027
   PubMed Web of Science ®Google Scholar
• Yeo D, Giardina C, Saxena P, Rasko JEJ. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics. 2022;24:561–576. doi:10.1016/j.omto.2022.01.010
   PubMed Web of Science ®Google Scholar
• Eibl G, Rozengurt E. Metformin: review of epidemiology and mechanisms of action in pancreatic cancer. Cancer Metastasis Rev. 2021;40(3):865–878. doi:10.1007/s10555-021-09977-z
   PubMed Web of Science ®Google Scholar
• Wang X, Li X, Wei X, et al. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Signal Transduct Target Ther. 2020;5(1):38. doi:10.1038/s41392-020-0144-8
   PubMed Web of Science ®Google Scholar
• Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605–618. doi:10.1016/j.trecan.2020.02.022
   PubMed Web of Science ®Google Scholar
• Cai Y, Ji W, Sun C, et al. Interferon-induced transmembrane protein 3 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors. Front Immunol. 2021;12:704965. doi:10.3389/fimmu.2021.704965
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang J, Chen H, et al. PSMC2 promotes the progression of gastric cancer via induction of RPS15A/mTOR pathway. Oncogenesis. 2022;11(1):12. doi:10.1038/s41389-022-00386-7
   PubMed Web of Science ®Google Scholar
• Smith DM, Fraga H, Reis C, Kafri G, Goldberg AL. ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle. Cell. 2011;144(4):526–538.
   PubMed Web of Science ®Google Scholar
• Song M, Wang Y, Zhang Z, Wang S. PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration. Oncotarget. 2017;8(1):933–953. doi:10.18632/oncotarget.13511
   PubMedGoogle Scholar
• Qin J, Wang W, An F, Huang W, Ding J. PSMC2 is up-regulated in pancreatic cancer and promotes cancer cell proliferation and inhibits apoptosis. J Cancer. 2019;10(20):4939–4946. doi:10.7150/jca.27616
   PubMed Web of Science ®Google Scholar
• Zhang G, Schetter A, He P, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 2012;7(2):e31507. doi:10.1371/journal.pone.0031507
   PubMed Web of Science ®Google Scholar
• Yang S, He P, Wang J, et al. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Cancer Res. 2016;76(13):3838–3850. doi:10.1158/0008-5472.CAN-15-2841
   PubMed Web of Science ®Google Scholar
• Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the Phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044–3050. doi:10.1093/annonc/mdx518
   PubMed Web of Science ®Google Scholar
• Blenman KRM, Marczyk M, Karn T, et al. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clin Cancer Res. 2022;28(12):2587–2597. doi:10.1158/1078-0432.CCR-21-3215
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D63. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7
   PubMed Web of Science ®Google Scholar
• Shen W, Song Z, Zhong X, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform. iMeta. 2022;1(3):e36. doi:10.1002/imt2.36
   Google Scholar
• Mei J, Fu Z, Cai Y, et al. SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. iScience. 2023;26(2):106027. doi:10.1016/j.isci.2023.106027
   PubMed Web of Science ®Google Scholar
• Sun D, Wang J, Han Y, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420–D30. doi:10.1093/nar/gkaa1020
   PubMed Web of Science ®Google Scholar
• Mei J, Cai Y, Xu R, et al. Protocol to identify novel immunotherapy biomarkers based on transcriptomic data in human cancers. STAR Protocols. 2023;4(2):102258. doi:10.1016/j.xpro.2023.102258
   PubMedGoogle Scholar
• Mei J, Wang R, Xia D, et al. BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma. DNA Cell Biol. 2020;39(10):1838–1849. doi:10.1089/dna.2020.5644
   PubMed Web of Science ®Google Scholar
• Cetin G, Klafack S, Studencka-Turski M, Kruger E, Ebstein F. The Ubiquitin-Proteasome System in Immune Cells. Biomolecules. 2021;11(1):60. doi:10.3390/biom11010060
   PubMed Web of Science ®Google Scholar
• Lalaoui N, Vaux DL. Recent advances in understanding inhibitor of apoptosis proteins. F1000Res. 2018;7:1889. doi:10.12688/f1000research.16439.1
   Google Scholar
• Kumar B, Field NS, Kim DD, et al. The ubiquitin ligase Cul5 regulates CD4(+) T cell fate choice and allergic inflammation. Nat Commun. 2022;13(1):2786. doi:10.1038/s41467-022-30437-x
   PubMed Web of Science ®Google Scholar
• Nijhawan D, Zack TI, Ren Y, et al. Cancer vulnerabilities unveiled by genomic loss. Cell. 2012;150(4):842–854. doi:10.1016/j.cell.2012.07.023
   PubMed Web of Science ®Google Scholar
• Zhu D, Huang J, Liu N, Li W, Yan L. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration. Cell Death Dis. 2021;12(8):730. doi:10.1038/s41419-021-03981-5
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu M, Li J, et al. Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU). Cell Death Dis. 2021;12(7):690. doi:10.1038/s41419-021-03960-w
   PubMed Web of Science ®Google Scholar
• Zheng X, Wang Y, Wang D, et al. PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells. World J Surg Oncol. 2022;20(1):84. doi:10.1186/s12957-022-02533-1
   PubMed Web of Science ®Google Scholar
• Yang Y, Qi F, Wei C, et al. PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma. Cell Death Discov. 2021;7(1):323. doi:10.1038/s41420-021-00727-2
   PubMed Web of Science ®Google Scholar
• Lee HH, Wang YN, Xia W, et al. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell. 2019;36(2):168–78 e4. doi:10.1016/j.ccell.2019.06.008
   PubMed Web of Science ®Google Scholar
• Mei J, Xu J, Yang X, et al. A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis. Mol Cancer. 2021;20(1):11. doi:10.1186/s12943-020-01304-4
   PubMed Web of Science ®Google Scholar